Shezad Malik Law Firm Dr Shezad Malik Law Firm has offices based in Fort Worth and Dallas and represents people who have suffered catastrophic and serious personal injuries including wrongful death, caused by the negligence or recklessness of others. We specialize in Personal Injury trial litigation and focus our energy and efforts on those we represent.

Invokana Diabetes Amputee Lawsuits

Invokana Diabetes Amputee Lawsuits. Michael Nickels recently filed a product liability and personal injury claim in the U.S. District Court for the District of New Jersey over claims of amputation as a result of taking the diabetic medication.

Invokana Diabetes Amputee Lawsuits

Invokana Diabetes Amputee Lawsuits. Invokana linked to kidney failure, leg amputations, and diabetic ketoacidosis according to lawsuits.

According to Nickels, Johnson & Johnson, the world’s largest pharmaceutical company, and its Janssen Pharmaceuticals subsidiary knew or should have known about the potential amputee side effects of Invokana, but withheld and hid information from patients and doctors about the severity of the amputee risks.

Mickels used Invonaka for the treatment of his type 2 diabetes in 2014, but within two years Mickels had to get an amputation procedure, from the use of the drug.

What is Invokana?

Invokana (canagliflozin) was released in March 2013 and is a new class of diabetes drugs, known as sodium-glucose cotransporter 2 (SGLT2) inhibitors. SGLT2 drugs work by affecting normal kidney functions to increase the release of sugar or glucose into the urine. SGLT2 class of drugs includes Invokamet, Jardiance, Farxiga, Xigduo and others, but Invokana the leader of the pack with blockbuster sales.

Over the last few years, many diabetic patients have switched to Invokana, from other diabetic medications such as Avandia (linked to cardiovascular side effects) and Actos (linked to bladder cancer).

Now severe Invokana side effects have been discovered including Invokana amputation risks, diabetic ketoacidosis, kidney failure, heart attacks and other catastrophic injuries.

FDA Invokana Diabetic Ketoacidosis Warnings

In December 2015, the FDA required Johnson & Johnson to add new diabetic ketoacidosis warnings to Invokana, highlighting that the medication significantly increases the risk of this potentially deadly condition.

Patients were advised by the FDA to stop taking Invokana and seek medical attention immediately if they have any symptoms of ketoacidosis, a condition when the body produces high levels of blood acids called ketones.

In June 2016, the FDA required additional label warnings about the link between Invokana and kidney risks, highlighting that the medication may increase the risk of acute kidney injury.

Invokana doubles Amputation risk of toes, feet, and legs

Based on new data from two large clinical trials, the FDA in May 2017 concluded that the type 2 diabetes medicines Invokana, Invokamet, Invokamet XR caused an increased risk of leg and foot amputations.

The FDA is requiring new warnings, including their most prominent Boxed Warning, to be added to the Invokana drug labels to describe this risk.

As patients become aware of the amputee side effects, injured patients are filing product liability lawsuits that claim that Invokana directly caused the amputation of their leg, foot or toes.

Invokana Diabetes Amputee Lawsuits 

Since December 2016, all federally-filed Invokana Diabetes Amputee Lawsuits have been consolidated as part of the federal Invokana multidistrict litigation (MDL), which is centralized before U.S. District Judge Brian Martinotti in the District of New Jersey to coordinate discovery and pretrial proceedings.

If you or someone you know succumbed to an Invokana Ketoacidosis, leg, foot, toes amputations or kidney failure from taking Invokana for the treatment of their type 2 diabetes, please call us for further information at 888-210-9693. Dr. Shezad Malik Law Firm is investigating Invokana Ketoacidosis, leg amputations or kidney failure from taking Invokana for the treatment of their type 2 diabetes.

Contact Information